Skip to main content
. 2016 May 9;7(23):33765–33782. doi: 10.18632/oncotarget.9260

Figure 1. Cisplatin impaired the phenotypic maturation of LPS-activated DCs by down-regulating the expression of CD80, CD86, MHC-I and II in a dose-dependent manner.

Figure 1

A.,B. CD11c+ immature BMDCs were cultured for 18 h in the presence of LPS (100 ng/ml), cisplatin (CP, 5 μg/mL), or LPS (100 ng/mL) with cisplatin (1, 2, and 5 μg/mL). The DCs were then stained with anti-CD80, anti-CD86, anti-MHC class I, or anti-MHC class II Abs. A. The surface marker expression of each DC set was compared to that of the controls. Isotype control (filled gray histogram), CON (non-stimulated DC, filled red histogram). B. The bar graphs show the mean ± SD (n = 3 samples) of the percentage of each surface molecule expressed by CD11c+ cells. The results are representative of three independent experiments. **p < 0.01 or ***p < 0.001 compared to DCs treated with LPS alone.